Scroll to explore

A unique GPCR company
dedicated to Immuno-Oncology

Our mission: delivering game-changing immunotherapies

We are committed to improve patients’ life and to support physicians by delivering innovative immunotherapies to fight cancer.

Our vision: unveiling the immune potential of GPCR

We aim at making an impactful difference for patients suffering from cancer by discovering first-in-class and best-in-class treatments to tackle GPCR-mediated immunosuppression.

Leveraging our expertise, innovative approach and proprietary platform, we develop a unique pipeline in immune-oncology and progress our most advanced programs towards the clinic.

Over the last decade, the company has also created a proprietary pipeline of GPCR-based programs in neurology and rare diseases. Domain is securing the development of these first-in-class assets by establishing early partnerships.

Our business model: corporate development and partnership

Domain Therapeutics is creating value for its shareholders by bringing to the clinic its proprietary portfolio of programs in immuno-oncology and by creating early partnerships on other assets in other non immuno-oncology therapeutic area.